A Single Dose, Phase 1 Study of YH35324 in Patients With Various Allergic Diseases
Status:
Recruiting
Trial end date:
2024-08-26
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) following a single subcutaneous injection of YH35324 in subjects with
various allergic diseases.